Cleanascite™Cited in the Preparation of Monoclonal Antibodies
MONMOUTHJUNCTION, NJ, October7, 2020 -- Biotech Support Group reports on a book chapter describingthe simplicity and efficiency of their lipid clearance samplepreparation technology for the preparation and storage of monoclonalantibodies. The citation is:
Collectingand Storing Hybridoma Tissue Culture Supernatants
ColdSpring Harb Protoc 2020.
©2020 Cold Spring Harbor Laboratory Press
Formost immunochemical methods, tissue culture supernatants will be themost useful source of monoclonal antibodies. The supernatants are notcontaminated with high levels of other antibodies, and theconcentration is high enough for most assays if used undiluted.Procedures for collecting tissue culturesupernatants are described. In the Troubleshooting section,the chapter states: “Problem (Step 7): A precipitate of lipidsand/or cryoproteins has formed.
Solution:This may be produced by long-term storage at 4°C. These precipitatescan be removed …using Cleanascite (Biotech Support Group; X2555)for clarification.”
“Withthe cost and complexity of producing pure monoclonal antibodies, itis essential to have methods that maintain high yields. Here isanother citation for the use of Cleanascite™ for the purpose ofremoving lipids and maintaining high recovery of monoclonalantibodies.” states Swapan Roy, Ph.D., President and Founder ofBiotech Support Group.
Formore information visit: Cleanascite™Lipid Removal Reagent and Clarification,at http://www.biotechsupportgroup.com/Cleanascite-Lipid-Removal-Reagent-p/x2555.htm
AboutBiotech Support Group LLC
Convergingwith cultural and technological disruptions forthcoming inhealthcare, Biotech Support Group develops methods for cost effectiveand efficient sample prep essential for these expanding markets.Following a tiered business strategy, the company continues itsgrowth in the consumable research products area supporting therapidly expanding installation of LC-MS instrument and computationalinfrastructure. For this market, key products include: AlbuVoid™and AlbuSorb™ for albumin depletion, Cleanascite™ for lipidadsorption, HemogloBind™ and HemoVoid™ for hemoglobin removal,and NuGel™ for functional proteomics. From these innovations, thecompany has acquired knowledgebase and biomarker intellectualproperty assets that support discoveries of protein markers fromblood, with special emphasis on early detection and personalizedmedical decisions for cancer patients. For more information, go tohttp://www.biotechsupportgroup.com/.
ForBusiness Development,contact:MatthewKuruc 732-274-2866, [email protected]